Biodistribution and Internal Radiation Dosimetry of (99m)Tc-IDA-D-[c(RGDfK)](2) (BIK-505), a Novel SPECT Radiotracer for the Imaging of Integrin α(v)β(3) Expression

(99m)Tc-IDA-D-[c(RGDfK)](2) (BIK-505) 的生物分布和内部辐射剂量测定,一种用于整合素 α(v)β(3) 表达成像的新型 SPECT 放射性示踪剂

阅读:1

Abstract

BACKGROUND: Integrin α(v)β(3) is a molecular marker for the estimation of tumor angiogenesis. (99m)Tc-IDA-D-[c(RGDfK)](2) (also known as BIK-505) is a recently developed radiotracer for single-photon emission computed tomography, with good affinity for integrin α(v)β(3). In this study, the authors investigated the whole-body distribution and internal radiation dosimetry of (99m)Tc-IDA-D-[c(RGDfK)](2) in elderly human participants. MATERIALS AND METHODS: Six healthy volunteers underwent whole-body simultaneous anterior and posterior scans, preceded by transmission scans using cobalt-57 flood source, with a dual head gamma camera system, at 0, 1, 2, 4, 8, and 24 h postinjection of (99m)Tc-IDA-D-[c(RGDfK)](2) (injected radioactivity [mean ± SD] = 388.7 ± 29.3 MBq). Anterior and posterior images were geometrically averaged and attenuation corrected to delineate the regions of interest in the liver, gallbladder, kidneys, urinary bladder, spleen, brain, and large intestine. Radiation dose for each organ and the effective doses (EDs) were estimated using OLINDA/EXM 1.1 software. RESULTS: High radiation doses of renal and biliary excretion tracks such as the urinary bladder wall, upper large intestine, kidneys, liver, and gallbladder wall (19.15 ± 6.84, 19.28 ± 4.78, 15.67 ± 0.90, 9.13 ± 1.71, and 9.09 ± 2.03 μGy/MBq, respectively) were observed. The ED and effective dose equivalent were 5.08 ± 0.53 and 7.11 ± 0.58 μSv/MBq, respectively. CONCLUSIONS: Dosimetry results were comparable to other radiolabeled peptides and were considered safe and efficient for clinical usage.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。